Young adult cancer survivors who had received their first rounds of cancer treatment between the ages of 20 and 44 were 1.5 times more likely to have more hospitalizations after remission than the general public.
Young adult cancer survivors who had received their first rounds of cancer treatment between the ages of 20 and 44 were 1.5 times more likely to have more hospitalizations after remission than the general public.
A new study published in the Journal of Clinical Oncology found that patients specifically with gastrointestinal cancer, leukemia, brain cancer, and lymphoma were twice as likely to be hospitalized at a greater rate, despite recent advances in cancer technology and treatment that have increased survival rates and life expectancy among young adults with cancer.
All patients with cancer, except for melanoma and testicular cancers, generally demonstrated significantly higher rates of hospitalization.
“Even when young adults survive cancer, the cancer still has an impact on their lives and their long-term health,” Nancy Baxter, colorectal surgeon at St. Michael’s Hospital and senior adjunct scientist at the Institute for Clinical Evaluative Sciences, said in a statement. “And this age group still has a lot of life to live.”
The authors noted that the findings mirrored a similar study that examined children diagnosed with cancer, which found that two-thirds of childhood cancer survivors developed long-term complications from cancer treatment, including chemotherapy, radiation, and surgery.
“The rate of hospitalization for 20-year survivors did not return to baseline, indicating a substantial and persistent burden of late effects among this generally young population,” the authors wrote.
Dr Baxter added that a better understanding of the late effects among the young adult cancer survivors may help to council the population on their future quality-of-life and may also steer them to options not closely linked with the long-term consequences demonstrated in the study.
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More
From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC
September 6th 2025Bispecific antibodies are emerging as a transformative class in advanced non–small cell lung cancer (NSCLC), with agents such as amivantamab and zenocutuzumab already demonstrating clinical benefit and a broad pipeline of investigational therapies showing promise in overcoming resistance.
Read More